LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Astria Therapeutics (ATXS – Research Report) today and set a price target of $22.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sam Slutsky has given his Buy rating due to a combination of factors including the promising developments in Astria Therapeutics’ clinical programs. The company has initiated its Phase 3 ALPHA-ORBIT trial for navenibart, a long-acting plasma kallikrein inhibitor, as a prophylactic treatment for hereditary angioedema (HAE). This trial is significant as it includes a comprehensive 6-month primary analysis and a flexible dosing long-term extension, aiming to enroll a substantial number of adult and adolescent patients.
Furthermore, the anticipation of key data releases, such as the topline results expected in early 2027, adds to the potential upside for the stock. Astria’s strategic focus on addressing unmet medical needs in HAE, coupled with its financial position, including a cash runway of approximately 2.3 years, supports the Buy rating. These factors collectively suggest a positive outlook for Astria Therapeutics, making it an attractive investment opportunity.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $35.00 price target.